
Conference Coverage
about 2 months ago
No HIV Infections Seen With Cabotegravir PrEP in Real-World Studyabout 2 months ago
Cabenuva Beats Daily Oral Therapy in Adolescents With HIV in LATA TrialLatest Content

Advertisement
Shorts

0:55
Early Aggressive Supportive Care Is Key to Surviving Ebola Infection
18 hours ago
by
Gavin H. Harris, MD(+1 more)

0:44
Who Keeps Food Safe?
6 days ago
by
Lynette Johnston, PhD(+1 more)

1:03
The Challenge of Capturing Complete Foodborne Numbers
7 days ago
by
Lynette Johnston, PhD(+1 more)

1:28
Can Monoclonal Antibodies Change Sudan Ebolavirus Treatment?
18 days ago
by
Gavin H. Harris, MD(+1 more)

1:01
Why Are Vaccine Rates Falling in the US?
20 days ago
by
Robert H. Hopkins Jr. MD(+1 more)

0:47
Physician Warns Kennedy Vaccine Task Force Is Poised to Undermine Immunization Schedule
a month ago
by
Jason Goldman, MD, MACP(+1 more)

1:11
Executive Orders vs Evidence: Why Vaccine Policy Must Follow the Science
a month ago
by
Jason Goldman, MD, MACP(+1 more)

0:47
Ceftriaxone Resistance in Gonorrhea Underscores Need for Diversified Regimens
2 months ago
by
Lao-Tzu Allan-Blitz, MD, MPH(+1 more)

1:11
DOTS Trial Data Support Dalbavancin As an Option for Staph bacteremia
2 months ago
by
Megan E. Klatt, PharmD, BCIDP, DPLA (+1 more)

1:37
PeterPEN Data Could Bring Piperacillin-Tazobactam Back
2 months ago
by
Megan E. Klatt, PharmD, BCIDP, DPLA (+1 more)
Contagion Digital Edition

Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.

In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.

Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.

A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.

A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.

Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.

Daptomycin-resistant Enterococcus faecium bacteremia is an emerging, high-mortality challenge in transplant and other high-risk patients, requiring early recognition, aggressive source control, and reliance on limited alternatives—most notably linezolid—with combination or salvage therapies considered when options are constrained.






























































































































































